AOM/DSS-treated chimeras with ST2-deficient hematopoietic cells had no alteration in CD4+ T cell frequencies, yet they showed a reduction of CD4+ FOXP3+ Tregs in intestinal tumors (Fig. 3h, i). This evidence concerns the gene IL1RL1 and intestinal neoplasm.